Dosing and administration

TEVIMBRA offers the most flexible set of dosing schedules of PD-1 inhibitors across its approved indications1-3

Select the dosing regimen that best fits your patients' and your practice's schedules1

TEVIMBRA® flexible dosing schedule chart

The overall management of certain adverse reactions may require treatment interruption or discontinuation, depending on severity.

For patients with 1L HER2+ GEA, TEVIMBRA can be synchronized with zanidatamab-hrii and chemotherapy on a Q2 or Q3W schedule1,4

Additional infusion considerations1:

  • Administer TEVIMBRA by IV infusion through an IV line with a sterile, nonpyrogenic, low-protein–binding, 0.2- or 0.22-micron in-line or add-on filter
    • For 150-mg and 200-mg doses, administer the initial infusion over 60 minutes. If tolerated, all subsequent infusions may be administered over 30 minutes
    • For 300-mg doses, administer the initial infusion over 90 minutes. If tolerated, administer the second infusion over 60 minutes. If the second infusion is tolerated, administer subsequent infusions over 30 minutes
    • For 400-mg doses, administer the initial infusion over 120 minutes. If tolerated, administer the second infusion over 60 minutes. If the second infusion is tolerated, administer subsequent infusions over 30 minutes

The overall management of certain ARs may require treatment interruption or discontinuation, depending on severity.

.

Leading Expert Explains Dosing Flexibility with TEVIMBRA

Ronan J. Kelly, MD, MBA, reviews dosing with TEVIMBRA, including its flexible regimen options across certain upper GI cancers.1

Combining TEVIMBRA with zanidatamab-hrii and chemotherapy4,5

  • When administering TEVIMBRA in combination with zanidatamab-hrii and chemotherapy: zanidatamab-hrii should be administered first, followed by TEVIMBRA, and then chemotherapy. For additional dosing and safety information, please refer to the zanidatamab-hrii Prescribing Information, including Boxed Warning
  • Patients in the zanidatamab-hrii–containing arms of the HERIZON-GEA-01 trial received mandatory prophylaxis for diarrhea (loperamide administered orally at 4 mg twice daily for the first 7 days of Cycle 1) and infusion-related reactions (glucocorticoids, antihistamines, and acetaminophen administered 30 to 60 minutes before infusion). Refer to the zanidatamab-hrii Prescribing Information for additional dosing information

Important reminders1

  • TEVIMBRA should be inspected visually for particulate matter and discoloration prior to administration
  • Do NOT coadminister other drugs through the same infusion line
  • Do NOT administer TEVIMBRA as an intravenous push or single bolus injection
  • The intravenous line must be flushed at the end of the infusion
  • TEVIMBRA is for single use only. Discard any unused portion left in the vial
Download the Dosing and
Administration Guide

Frequently Asked Questions

Expand All

TEVIMBRA offers the most flexible set of dosing regimens across its approved indications, providing convenient treatment planning. You can synchronize TEVIMBRA with your preferred chemotherapy following a Q2W or Q3W schedule and offer convenience with fewer infusion visits for patients following a Q4W or Q6W schedule.1-3

TEVIMBRA is administered as an IV infusion.1

TEVIMBRA offers a flexible set of dosing regimens across indications with options for Q2W, Q3W, Q4W, or Q6W schedules. For 150-mg and 200-mg doses, if the first 60-minute infusion is tolerated, subsequent doses may be administered over 30 minutes. For 300-mg doses, if the first 90-minute infusion is tolerated, the second infusion may be administered over 60 minutes. If the second infusion is tolerated, subsequent doses may be administered over 30 minutes. For 400-mg doses, if the first 120-minute infusion is tolerated, the second infusion may be administered over 60 minutes. If the second infusion is tolerated, subsequent doses may be administered over 30 minutes.1

For patients with 1L HER2+ advanced GEA, TEVIMBRA dosing can be synchronized with zanidatamab-hrii and chemotherapy on a Q2W or Q3W schedule. When administering TEVIMBRA in combination with zanidatamab-hrii and chemotherapy, zanidatamab-hrii should be administered first, followed by TEVIMBRA, and then chemotherapy. For additional dosing and safety information, please refer to the zanidatamab-hrii Prescribing Information, including Boxed Warning.1,4

View dosing modifications

*Fluoropyrimidine- and platinum-containing chemotherapy for 1L HER2+ GEA; fluoropyrimidine- and platinum-containing chemotherapy for 1L HER2- GC/GEJC; platinum-containing chemotherapy for 1L ESCC.1

AR, adverse reaction; ESCC, esophageal squamous cell cancer; GI, gastrointestinal; IV, intravenous; Q2W, every 2 weeks; Q3W, every 3 weeks; Q4W, every 4 weeks; Q6W, every 6 weeks.

References: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2026. 2. Keytruda. Prescribing Information. Merck & Co. Inc.; 2026. 3. Opdivo. Prescribing Information. Bristol-Myers Squibb Company; 2026. 4. Ziihera. Prescribing Information. Jazz Pharmaceuticals, Inc.; 2026. 5. Shitara K, Elimova E, Liu T, et al. N Engl J Med. 2026;394(20):2002-2014. doi:10.1056/NEJMoa2517729

You are being redirected to nccn.org

Continue
Cancel
This site is intended for US healthcare professionals only. Please confirm you are a US healthcare professional.
test
Visit the patient site

You are being redirected to myBeOneSupport.com

Continue
Cancel